The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://mollyhbvn240600.wikiparticularization.com/2028202/glp_3_retatrutide_a_comparative_analysis